Stuttgart – ESE GmbH’s shareholders have sold their shares to Qiagen Deutschland Holding GmbH, a subsidiary of listed company Qiagen N.V. The transaction extends Qiagen's portfolio of test technologies by adding an innovative detection platform developed by ESE, and is valued at up to USD 19 million in cash.
A team from CMS Hasche Sigle led by lead partner Dr Regine Hagen-Eck advised the sellers of ESE GmbH on all aspects of the transaction.
Based in Stockach on Lake Constance, Germany, technology company ESE GmbH has so far been privately owned. It has pioneered the development and manufacture of fluorescence-based sensor measurement systems for medical and industrial applications. ESE's systems are considered as an emerging standard for the detection of fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acid-based point-of-need testing.
The acquisition gives Qiagen the opportunity to enter selected market segments with potential for point-of-need testing solutions based on molecular technologies. With operational headquarters in Hilden, Germany, Qiagen is the leading global provider of sample and assay technologies. The company employs more than 3,400 people at over 30 locations worldwide.
Advisers CMS Hasche Sigle:
Dr Regine Hagen-Eck, Corporate/M&A (Lead Partner)
Marcell Baumann, Corporate/M&A
Roland Wutzke, Tax
Dr Matthias Eck, IP
Dr Werner Walk, Employment Law
Dr Regine Hagen-Eck
+49 711 9764 408